tbuckley/cabot-search huggingface dataset:
Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.
Authors: Paul Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson
Journal: Blood (2004)
Cardiovascular and Ventilatory Consequences of Laparoscopic Surgery
Authors: Tamara M. Atkinson, George D. Giraud, Brandon M. Togioka, Daniel B. Jones, Joaquin E. Cigarroa
Journal: Circulation (2017)

Although laparoscopic surgery accounts for >2 million surgical procedures every year, the current preoperative risk scores and guidelines do not adequately assess the risks of laparoscopy. In general, laparoscopic procedures have a lower risk of morbidity and mortality compared with operations requiring a midline laparotomy. During laparoscopic surgery, carbon dioxide insufflation may produce significant hemodynamic and ventilatory consequences such as increased intraabdominal pressure and hypercarbia. Hemodynamic insults secondary to increased intraabdominal pressure include increased afterload and preload and decreased cardiac output, whereas ventilatory consequences include increased airway pressures, hypercarbia, and decreased pulmonary compliance. Hemodynamic effects are accentuated in patients with cardiovascular disease such as congestive heart failure, ischemic heart disease, valvular heart disease, pulmonary hypertension, and congenital heart disease. Prevention of cardiovascular complications may be accomplished through a sound understanding of the hemodynamic and physiological consequences of laparoscopic surgery as well as a defined operative plan generated by a multidisciplinary team involving the preoperative consultant, anesthesiologist, and surgeon.
CBIO-17. STAT3 IS A CENTRAL REGULATOR OF PROLIFERATION, INVASION, MIGRATION AND METABOLISM IN GBM TUMOR INITIATING CELLS
Authors: Ian Restall, H. Artee Luchman, Samuel Weiss
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme (GBM) is the most aggressive adult primary brain tumor. Currently, treatment for GBM involves surgical resection, chemotherapy, and radiation, resulting in a median survival of 15 months. This poor outcome highlights the need for improved therapeutic approaches to treat GBM patients. The signal transducer and activator of transcription 3 (STAT3) pathway is abnormally active in GBM, primarily in the mesenchymal subtype. STAT3 regulates various cellular processes including: proliferation, migration, invasion and resistance to therapy. The Weiss lab has established a large collection of brain tumor initiating cell (BTIC) lines derived from GBM patients. Here, we are focused on the role of STAT3 as a central regulator of the above cellular processes and of metabolism in GBM BTIC lines. We show that activation of the STAT3 pathway using exogenous cytokines leads to an increase in proliferation, invasion, and migration of BTICs. Using time-lapse imaging of 3D sphere invasion into a matrix, we observed that chemical inhibitors of JAK2 (an activator of STAT3) and of STAT3 decrease invasion of BTICs. Interestingly, our analysis of GBM patient sample gene expression data available from The Cancer Genome Atlas (TCGA) further demonstrates that a STAT3 gene expression signature correlates significantly with various metabolic pathways. We hypothesize that targeting the STAT3 pathway will decrease proliferation, invasion, and migration while simultaneously modulating BTIC metabolism. Initial work has shown a range of sensitivity to inhibitors of glycolysis and glutaminolysis in a genetically diverse set of 10 BTIC lines. Ongoing work is being performed to assess the effect of activating or inhibiting the STAT3 pathway to modulate the sensitivity of BTICs to these inhibitors. Overall, we have observed that STAT3 is a central hub in GBM BTICs that modulates proliferation, invasion, migration and metabolism. Currently, we are continuing in vivo experiments using BTIC orthotopic xenografts in mice.
Feasibility study of dose dense epirubicin and cyclophosphamide in the primaly breast cancer treatment
Authors: Sachi Morita, Takahiro Inaishi, Akiko Ota, Ayumu Matsuoka, Takehumi Mizutani, Tomoya Shimokata, Osamu Maeda, Ayako Mitsuma, Nobuyuki Tsunoda, Toyone Kikumori, Yuichi Ando
Journal: Annals of Oncology (2016)
Important Role of Early Therapy and Maintaining Uninterrupted Treatment In the Outcomes of Chronic Myelogenous Leukemia Patients Treated with Imatinib
Authors: Erica Lammerhirt Ottoni, Marcelo Capra, Mariza Schaan, Marco Antônio Schilling, Katia Fassina, Mario Sérgio Fernandes, Denise Almeida, Moema Nene, Tânia Hellwig, Tito Vanelli Costa, Adriana Zardo, Andréia Dias Almeida, Gilca Nachtigal, Christina G S Fraga, Liane Esteves Daudt, Lucia Silla, Laura Fogliatto
Journal: Blood (2010)
Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).
Authors: Robert M. Dean, Daniel Fowler, Wyndham H. Wilson, Frances Hakim, Seth Steinberg, Jeanne Odom, Catherine Chow, Claude Sportes, Juan Gea-Banacloche, Steven Z. Pavletic, Nancy M. Hardy, Ronald Gress, Michael R. Bishop
Journal: Blood (2006)
Combination High-Dose Cyclophosphamide and Bortezomib Is Safe and Effective for Stem Cell Harvesting in Chemotherapy Refractory Multiple Myeloma.
Authors: Miriam Katzman, Theresa George, Heather Doell, Patricia Danyluk, Sheri Briggs, Wanda Hasegawa, Christian Fibich, Michael Voralia
Journal: Blood (2006)
Adoptive Immune Cell Therapy for the Control of Fungal Infections in Hematopoietic Stem Cell Transplant Patients
Authors: Lung-Ji Chang, Yin Liang, Lily Lien, Chun- Rong Tong, Lu-Jia Dong, Tong Wu, Yinchieh Fu, Fu-Hung Yang, Jih-Luh Tang, Dao-Pei Lu
Journal: Blood (2008)
Highly-Purified Aspergillus Fumigatus Specific T-Cells as a Potential Treatment Option of Invasive Aspergillosis.
Authors: Olaf R. Beck, Max S. Topp, Ulrike Koehl, Mitra Hanisch, Holger F. Hebart, Jean-Paul Latge, Hermann Einsele, Thomas Klingebiel, Thomas Lehrnbecher
Journal: Blood (2004)
Expression of Gli2, a Downstream Mediator of the Activated Hedgehog Pathway, Represents a Negative Prognostic Marker in AML,
Authors: Walter Fiedler, Gabi Vohwinkel, Juergen Krauter, Eik Vettorazzi, Sonja Loges, Livia Fuhrmann, Patrizia Seyfert, Carsten Bokemeyer, Jasmin Wellbrock
Journal: Blood (2011)
Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)
Authors: F. Cappuzzo, R. Soo, M. Hochmair, M. Schuler, T.S.K. Mok, G. Stehle, A. Cseh, R.M. Lorence, S. Linden, N.D. Forman, C.-M. Tsai
Journal: Annals of Oncology (2016)
High dosages of the fixed combination OXYCODONE/NALOXONE in cancer pain: mid-term efficacy and tolerability
Authors: S. Ceniti, F. Amato, S. Mameli, G.M. Pisanu, R. Vellucci, V. Palmieri, L. Consoletti, D. Magaldi, P. Notaro, S. Conforti
Journal: Annals of Oncology (2016)
Assessment of PD-L1 and CD47 expression together with tumor-associated TILs in resectable early stage NSCLC
Authors: S. Hall, L. Wang, T. Marti, R.-W. Peng, L. Froment, S. Berezowska, G. Kocher, P. Dorn, R.A. Schmid
Journal: Annals of Oncology (2016)
Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom
Authors: Mark T Gladwin, Robyn J Barst, J. Simon R. Gibbs, Marianna Hildesheim, Vandana Sachdev, Mehdi Nouraie, Kathryn L. Hassell, Jane A. Little, Dean E. Schraufnagel, Lakshmanan Krishnamurti, Enrico M Novelli, Reda E. Girgis, Yingze Zhang, Claudia R. Morris, Erika Berman Rosenzweig, David B. Badesch, Sophie Lanzkron, Oswaldo L Castro, James G. Taylor, Jonathan C. Goldsmith, Victor R. Gordeuk, Gregory J. Kato, Roberto Machado
Journal: Blood (2012)
OS6.8 Family caregivers’ level of mastery predicts survival of glioblastoma patients
Authors: F. W. Boele, C. W. Given, B. A. Given, H. S. Donovan, R. Schulz, J. Weimer, J. Drappatz, F. S. Lieberman, P. R. Sherwood
Journal: Neuro-Oncology (2016)
Associations between deepness of response and clinical outcomes with advanced HER2-positive gastric cancer with 1st-line chemotherapy and trastuzumab
Authors: H. Osumi, E. Shinozaki, K. Chin, M. Ogura, T. Matsushima, T. Wakatsuki, I. Nakayama, T. Ichimura, D. Takahari, K. Yamaguchi
Journal: Annals of Oncology (2016)
Exhaled Nitric Oxide (eNO) and Pulmonary Function after Total Body Irradiation (TBI) Based Non Myeloablative Conditioning Regimens and Allogeneic Hematopoietic Cell Transplant.
Authors: Luisa Giaccone, Caterina B. Bucca, Roberto Sorasio, Marcello Rotta, Gabriele Aitoro, Erica Panaro, Luisa Brussino, Giovanni Rolla, Mario Boccadoro, Benedetto Bruno
Journal: Blood (2005)
Red Cell Transfusion Support for Hematology and Oncology Patients Is Both Substantial and Often Required Urgently. Results from the Bloodhound Study: A Comprehensive, Prospective Australian Study of Red Cell Use
Authors: Jake Shortt, Neil Waters, Mary Comande, Mark N Polizzotto, Martine Moran, Marija Borosak, Damien J Jolley, Erica M Wood
Journal: Blood (2008)
P17.05 Epidemiology and clinical in patients with primary and secondary lymphomas with a nervous system condition in the South Central Hospital of High Specialty from PEMEX in Mexico
Authors: M. Cordoba Mosqueda, J. Guerra Mora, R. Hernandez Resendiz, I. Loya Aguilar, R. Vicuña Gonzalez, A. Ibarra de la Torre, U. Garcia Gonzalez
Journal: Neuro-Oncology (2016)
Intra-Clonal Heterogeneity Is a Critical Early Event in the Preclinical Stages of Multiple Myeloma and Is Subject to Darwinian Fluctuation throughout the Disease
Authors: Lorenzo Melchor, Brian A Walker, Christopher P Wardell, Annamaria Brioli, Martin F Kaiser, Lucía López-Corral, Sean Humphray, Lisa Murray, Mark Ross, David Bentley, Ramón García-Sanz, Jesús F San Miguel, Faith E. Davies, David Gonzalez, Gareth J. Morgan
Journal: Blood (2012)
Taselisib enhances effects of anti-microtubule chemotherapic agents in phosphatidylinositol 3-kinase (PI3K&amp;agr;) mutant breast cancer cell lines
Authors: A. Diana, F. Morgillo, C.M. Della Corte, C. Di Mauro, V. Ciaramella, F. De Vita, F. Ciardiello, M. Orditura
Journal: Annals of Oncology (2016)
Aberrant Cell Cycle and Expression Profiles of Cell Cycle Regulatory Genes in Myelodysplastic Syndrome.
Authors: Zonghong Shao, Jun Shi, Hong Liu, Juan Sun, Hairong Jia, Jie Bai, Guangsheng He, Yanran Cao, Meifeng Tu, Huaquan Wang, Liming Xing
Journal: Blood (2005)
IGHV-D-J Ultra-Deep Sequencing Reveals APOBEC and AID Targeted Mutations during Clonal Evolution of CLL in a Xenograft Mouse Model
Authors: Charles C. Chu, Piers E.M. Patten, Thomas MacCarthy, Chaohui Yuan, Xiao-Jie Yan, Jacqueline C. Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2014)
EPID-14. RISK FACTOR ANALYSIS AND OUTCOMES IN PATIENTS WITH HIGH GRADE GLIOMAS (HGG) MANAGED AT ALLEGHENY GENERAL HOSPITAL (AGH) IN PITTSBURGH, PA
Authors: Nawaal Shaikh, Carol Schramke, Khaled Aziz, Alexander Yu, David Jho, Stephen Karlovits, Russell Fuhrer, Cunfeng Pu, Larisa Greenberg, Tulika Ranjan
Journal: Neuro-Oncology (2016)

Many genetic and environmental factors have been studied in glioblastoma multiforme (GBM), but majority are sporadic and no risk factor accounting for a large proportion of GBMs has been identified except for ionizing radiation. Median survival of patients with GBM is 14.6 months and is 9.4 months for unresectable GBM. The incidence of unresectable GBM is around 17% and multifocal GBM at the time of diagnosis is around 0.5 to 35 %. Retrospective chart review and a prospective telephonic survey was performed at AGH. Patients aged 18-100 years, diagnosed between Jan 2014 to March 2016, with HGG (GBM, anaplastic astrocytoma AA, or anaplastic oligodendroglioma AO) were included. Of the total 117 patients identified 84% had GBM. Frontal and temporal lobes were the most common locations. Based on MR imaging review 20% had multifocal and 43.6% had unresectable tumor. On molecular analysis 33% of unmethylated MGMT gene promotor status, 44% of IDH1 negative, 47% of p53 positive and 47% of ATRX positive patients had unresectable disease. Median overall survival was 6.2 months for unresectable tumor. Telephonic survey have been conducted on 56 patients thus far. Of the 56 patients 42% were tobacco abusers, 14% had prior cancer history, 29% had asbestos exposure, 23% had some form of carbon disulphide exposure, 46% were well water drinkers, 63% had heavy mobile phone usage, 70% had significant cordless phone usage and 30% were exposed to extremely low frequency radiation(ELF) through occupation. At AGH, incidence of multifocal disease is within the reported national average range but proportion of unresectable disease is high when compared to Stupp data. Well water, mobile phone and cordless phone usage, exposure to asbestos and ELF are factors that need to be studied further.
Biomarker analysis to predict the pathological response of locally advanced gastric cancer to neoadjuvant chemotherapy: an exploratory study of the randomized phase II COMPASS trial
Authors: K. Tanabe, T. Yoshikawa, T. Oshima, Y. Miyagi, S. Morita, K. Nishikawa, Y. Ito, T. Matsui, Y. Kimura, T. Aoyama, T. Hayashi, T. Ogata, H. Cho, A. Tuburaya, J. Sakamoto
Journal: Annals of Oncology (2016)
Familial Essential Thrombocythemia Showing Spontaneous Megakaryocyte Colony Formation and Acquired JAK2 Mutations without a Germline Mutation in C-MPL or TPO.
Authors: Jillian R. Higgs, Irene Sadek, Paul E. Neuman, Vincent Ing, Jason N. Berman, Wenda L. Greer
Journal: Blood (2007)
Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.
Authors: Jose Cervera, Guillermo Martin, Jesus M. Hernandez, Edo Vellenga, Maria J. Calasanz, Jose A. Martinez-Climent, Elisa Luño, Maria T. Ferro, Consuelo Rayon, Marcos Gonzalez, Mar Tormo, Concha Rivas, Elena Amutio, Javier de la Serna, Jose D. Gonzalez-San Miguel, Juan Bergua, Angel Leon, Joaquin Diaz-Mediavilla, Jose Garcia-Laraña, Jordi Esteve, Miguel A. Sanz
Journal: Blood (2004)
P14.06 Clinical and instrumental characterization of patients with radiation necrosis after proton/carbon ion therapy: a cohort preliminary analysis
Authors: L. Diamanti, G. Berzero, P. Bini, S. Bernini, E. Sinforiani, C. Galimberti, A. Iannalfi, E. Ciurlia, V. Vitolo, G. Viselner
Journal: Neuro-Oncology (2016)
Pure Hematopoietic Stem Cells Reconstitute Immunity in Allogeneic Hosts Superior to Bone Marrow: Immunosuppression by Subclinical Graft-Versus-Host Disease.
Authors: Gabriel J. Tsao, Jessica A. Allen, Kathryn Logronio, Laura C. Lazzeroni, Judith A. Shizuru
Journal: Blood (2007)
MNGO-08. TRANSCRIPTIONAL CHARACTERIZATION OF MENINGIOMA PROGRESSION
Authors: Maria Martinez-Lage, Jayesh Thawani, Yuankun Zhu, Bo Zhang, Robert Bailey, Laura Roccograndi, Donald M. O’Rourke, Adam C Resnick, M. Sean Grady, Nadia Dahmane
Journal: Neuro-Oncology (2016)

Meningiomas are the most common adult primary tumors in the nervous system, accounting for more than 30% of all brain tumors. Meningiomas arise from arachnoid cells and while the majority is benign (WHO Grade I), about 20% (WHO Grades II and III) are considered aggressive. Grade II and III tumors are heterogeneous and present characteristics of aggressiveness including proliferation, brain invasion and increased risk of recurrence. In rare cases grades II and III meningiomas develop in the setting of a prior lower grade meningioma. Mechanisms leading to tumor progression or implicated in de novo grade II and III meningiomas are poorly understood. RNAseq was used to profile the transcriptome of grade I, II and III meningiomas (total 26 samples: 9 grade I, 11 grade II and 6 grade III) and to identify genes and pathways that may be involved in meningioma genesis and progression. Three of the grade I tumors showed progression and the resulting grade II tumors were also analyzed for distinct signature patterns. In addition, our study included meningiomas with (n=9) or without (n=12) brain invasion. Following bioinformatic analyses, including hierarchical cluster analysis and Gene Set Enrichment Analysis (GSEA) of the RNAseq data, our data demonstrate that each meningioma grade and each invasion status may be identified by specific gene expression programs. In addition, the RNAseq data was used to detect mutations not only in known genes associated with meningioma development such as NF2 or SMO but also in novel potential regulators of meningioma progression.
Systematic reviews and meta-analyses on psoriasis: role of funding sources, conflict of interest and bibliometric indices as predictors of methodological quality
Authors: F. Gómez-García, J. Ruano, M. Aguilar-Luque, J. Gay-Mimbrera, B. Maestre-Lopez, J.L. Sanz-Cabanillas, P.J. Carmona-Fernández, M. González-Padilla, A. Vélez García-Nieto, B. Isla-Tejera
Journal: British Journal of Dermatology (2017)

The quality of systematic reviews and meta-analyses on psoriasis, a chronic inflammatory skin disease that severely impairs quality of life and is associated with high costs, remains unknown.To assess the methodological quality of systematic reviews published on psoriasis.After a comprehensive search in MEDLINE, Embase and the Cochrane Database (PROSPERO: CDR42016041611), the quality of studies was assessed by two raters using the Assessment of Multiple Systematic Reviews (AMSTAR) tool. Article metadata and journal-related bibliometric indices were also obtained. Systematic reviews were classified as low (0-4), moderate (5-8) or high (9-11) quality. A prediction model for methodological quality was fitted using principal component and multivariate ordinal logistic regression analyses.We classified 220 studies as high (17·2%), moderate (55·0%) or low (27·8%) quality. Lower compliance rates were found for AMSTAR question (Q)5 (list of studies provided, 11·4%), Q10 (publication bias assessed, 27·7%), Q4 (status of publication included, 39·5%) and Q1 (a priori design provided, 40·9%). Factors such as meta-analysis inclusion [odds ratio (OR) 6·22; 95% confidence interval (CI) 2·78-14·86], funding by academic institutions (OR 2·90, 95% CI 1·11-7·89), Article Influence score (OR 2·14, 95% CI 1·05-6·67), 5-year impact factor (OR 1·34, 95% CI 1·02-1·40) and article page count (OR 1·08, 95% CI 1·02-1·15) significantly predicted higher quality. A high number of authors with a conflict of interest (OR 0·90, 95% CI 0·82-0·99) was significantly associated with lower quality.The methodological quality of systematic reviews published about psoriasis remains suboptimal. The type of funding sources and author conflicts may compromise study quality, increasing the risk of bias.
Opioid-Prescribing Patterns of Emergency Physicians and Risk of Long-Term Use
Authors: Michael L. Barnett, Andrew R. Olenski, Anupam B. Jena
Journal: New England Journal of Medicine (2017)

Increasing overuse of opioids in the United States may be driven in part by physician prescribing. However, the extent to which individual physicians vary in opioid prescribing and the implications of that variation for long-term opioid use and adverse outcomes in patients are unknown.We performed a retrospective analysis involving Medicare beneficiaries who had an index emergency department visit in the period from 2008 through 2011 and had not received prescriptions for opioids within 6 months before that visit. After identifying the emergency physicians within a hospital who cared for the patients, we categorized the physicians as being high-intensity or low-intensity opioid prescribers according to relative quartiles of prescribing rates within the same hospital. We compared rates of long-term opioid use, defined as 6 months of days supplied, in the 12 months after a visit to the emergency department among patients treated by high-intensity or low-intensity prescribers, with adjustment for patient characteristics.Our sample consisted of 215,678 patients who received treatment from low-intensity prescribers and 161,951 patients who received treatment from high-intensity prescribers. Patient characteristics, including diagnoses in the emergency department, were similar in the two treatment groups. Within individual hospitals, rates of opioid prescribing varied widely between low-intensity and high-intensity prescribers (7.3% vs. 24.1%). Long-term opioid use was significantly higher among patients treated by high-intensity prescribers than among patients treated by low-intensity prescribers (adjusted odds ratio, 1.30; 95% confidence interval, 1.23 to 1.37; P<0.001); these findings were consistent across multiple sensitivity analyses.Wide variation in rates of opioid prescribing existed among physicians practicing within the same emergency department, and rates of long-term opioid use were increased among patients who had not previously received opioids and received treatment from high-intensity opioid prescribers. (Funded by the National Institutes of Health.).
Interleukin-1 Receptor Antagonist and Interleukin-1 beta: Different Roles in Patients with Chronic Lymphocytic Leukemia.
Authors: Zhong Zhang, Susan O’Brien, Michael Keating, Iman Jilani, Hagop Kantarjian, Zeev Estrov, Alessandra Ferrajoli, Francis Giles, Maher Albitar
Journal: Blood (2006)
ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG)
Authors: Timothy Cloughesy, Tobias Walbert, Daniela Bota, Michael Vogelbaum, Linda Liau, Derek Ostertag, Douglas Jolly, Harry Gruber, Liqiang Yang, Jolene Shorr, Steven Kalkanis
Journal: Neuro-Oncology (2016)

Recurrent HGG remains resistant to therapy with survival ranging from 7.2–9.2 months. An ongoing clinical study (NCT01985256) using a retroviral replicating vector (RRV), Toca 511, in combination with oral Toca FC (extended-release 5-fluorocytosine [5-FC]) is evaluating the highest tolerated doses and viral pharmacokinetics in patients with recurrent HGG. Toca 511 (vocimagene amiretrorepvec) encodes a yeast-derived, codon-optimized, heat-stabilized cytosine deaminase (CD) that converts 5-FC to the anti-cancer drug 5-FU in infected tumors. Toca 511 was intravenously administered over 1, 3, or 5 days with subsequent tumor resection and injection of Toca 511 into resection cavity walls. Six weeks later Toca FC was administered for 7 days every 6 weeks. Resected tumor was evaluated for presence of virus and transgene. Tumor samples have demonstrated presence of viral DNA signal in a dose dependent manner with 14/17 (82%) detectable overall of which 7/9 (78%) were in subjects treated with 3-day delivery and 100% (3/3) with 5-day delivery. Quantifiable viral DNA was found in 8/17 (47%) overall of which 5/9 (56%) was in the 3-day and 2/3 (67%) in the 5-day IV cohorts. Expression of the transgene was detectable by IHC. Five weeks after Toca 511 injection, viral RNA could not be detected in blood above the lower quantification limit. Median overall survival for efficacy evaluable population is 13.6 months (95% CI 7.2, NR). Based on 11 subjects evaluated by independent radiology review, 1 was reported to have a radiologic CR (with an unrelated stroke) and 2 to have stable disease. Safety data to date shows good tolerability with low grade pyrexia (n=2, 18.2%) and related SAEs of cerebral cyst and vasogenic edema. This study demonstrates successful gene transduction following IV delivery of Toca 511 and shows encouraging survival data. Updated safety and efficacy data will be presented.
Successful Engrafment After HLA Identical Granulocyte Transfusion As Support Therapy in a Septic Shock Patient with Acute Lymphoblastic Leukemia
Authors: Roberto Ovilla, Claudia Barrera-Carmona, Nicolas Guzman-Bouilloud, Elizabeth Buganza-Torio, Rosa Jimenez-Alvarado, Claudia Monreal-Alcantara
Journal: Blood (2012)